Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of AZD9550 in Healthy Participants
NCT05848440Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2023
- Primary completion
- Nov 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD9550 in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by AstraZeneca. Primary endpoint: Adverse Events and Serious Adverse Events up to 6 months. Started May 2023; status: completed.
02
Drugs
AZD9550
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05848440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05848440.